Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H19N3OS.ClH |
| Molecular Weight | 325.857 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)C(=O)NC1=CC(=CC=C1)[C@H]2CN3CCSC3=N2
InChI
InChIKey=FXYKKPLSQTYWRY-BTQNPOSSSA-N
InChI=1S/C15H19N3OS.ClH/c1-10(2)14(19)16-12-5-3-4-11(8-12)13-9-18-6-7-20-15(18)17-13;/h3-5,8,10,13H,6-7,9H2,1-2H3,(H,16,19);1H/t13-;/m1./s1
DescriptionCurator's Comment: Description was created based on several sources, including https://books.google.ru/books?id=nq6Zeo5vng8C&pg=PA5144&lpg=PA5144&dq=BUTAMISOLE retrieved from Molecular Biochemistry and Physiology of Helminth Neuromuscular Systems
edited by David Halton, p.5144
Curator's Comment: Description was created based on several sources, including https://books.google.ru/books?id=nq6Zeo5vng8C&pg=PA5144&lpg=PA5144&dq=BUTAMISOLE retrieved from Molecular Biochemistry and Physiology of Helminth Neuromuscular Systems
edited by David Halton, p.5144
Butamisole is an injectable imidazothiazoles anthelmintic. In dogs it is used for the treatment of infections with whipworms (Trichuris vulpis ), and the hookworm (Ancylostoma caninum ). Nicotinic acetylcholine receptor agonist. Acts as agonist at nicotinic Ach receptor of nematode à ganglionic stimulation causes sustained muscle contraction initially followed by depolarising neuro muscular blockade which in turn leads to spastic paralysis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1884 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Butamisole Approved UseIndications for use. For the treatment of infections with whipworms (Trichuris vulpis), and the hookworm (Ancylostoma caninum). |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Anthelmintic actions on homomer-forming nicotinic acetylcholine receptor subunits: chicken alpha7 and ACR-16 from the nematode Caenorhabditis elegans. | 2000 |
|
| The efficacy and safety of injectable butamisole in dogs. | 1979-04 |
|
| Critical test evaluation of butamisole against gastrointestinal parasites of horses and ponies. | 1979-01 |
Patents
Sample Use Guides
Dogs: Administer 0.1 mg per pound of body weight by subcutaneous injection. In problem cases, retreatment for whipworms may be necessary in approximately 3 months. For hookworms, a second injection should be given 21 days after the initial treatment.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11113327
Butamisole was without agonist actions on either alpha7 or ACR-16 chicken nicotinic receptors in the range 10nM-1mM. However, butamisole (pIC(50)=4.9 for both alpha7 and ACR-16) antagonized responses of both alpha7 and ACR-16 receptors to acetylcholine. Application of butamisole
in the concentration range 0.1 um-100 um for 30 s prior
to application of 1 mM ACh in the continued presence of
butamisole resulted in a dose-dependent reduction in the
ACh current amplitude recorded from both receptors.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 522.234
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
76964744
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
PRIMARY | |||
|
DTXSID30969535
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
PRIMARY | |||
|
54400-62-3
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
PRIMARY | |||
|
m1048
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
C020238
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
PRIMARY | |||
|
300000055309
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110807
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
PRIMARY | |||
|
QGM18599H5
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
PRIMARY | |||
|
C79919
Created by
admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD